Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Vyome is buying its way into a large, fast‑growing immunology market with next‑generation, more selective JAK inhibitors, without overextending its balan...
Key Highlights: Implications: Triple Hair is turning TH07 into a genuinely global late‑stage asset in male pattern hair loss by running synchronized Phase III trials in Canada and In...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
Key Highlights Implications: Lormalzi gives Lilly an early foothold in India’s tiny but fast‑growing market for disease‑modifying Alzheimer’s drugs, while it test...
Key Highlights: Implications: With legal access to the Charpentier CRISPR/Cas9 patents, Aurigene can now run gene‑editing projects (target validation, disease models, f...
Key Highlights Implications: Indoco is effectively cashing out of a non-core, lower-scale ophthalmic franchise (₹110 crore slump sale) to refocus capital and management on highe...
Key Highlights: Implications: EssilorLuxottica is using Essilor Stellest to move India’s pediatric myopia market from simple correction to active control, position...
Key Highlights: Implications: Sun Pharma is making its biggest strategic pivot yet with the planned all‑cash takeover of Organon, using the deal to jump from an India‑anchor...
Key Highlights: Implications: Zintrodiazine’s Phase III go‑ahead positions Zydus as a front‑line Indian innovator in a space long dominated by global public–privat...
